← Azimuth Daily
Capturing data…
Capturing data…
SUN, 25 OCT · 77 ITEMS
"Anbenitamab plus HB1801 for HER2-positive advanced breast cancer shows efficacy" — NEJM (eTOC) · Science & Medicine
This is a report from the New England Journal of Medicine on clinical trial results for the combination of (a bispecific antibody targeting HER2) plus (a formulation of the chemotherapy docetaxel) in patients with . The data show efficacy, likely measured as tumor response or progression-free survival, supporting this combination as a potential treatment option.
The claim is directly from the primary source: the published trial paper in NEJM (NEJMoa2610345). As a peer-reviewed journal article, the efficacy data and conclusions are as reported by the authors and subject to editorial scrutiny, making the claim reliable at the level of the publication itself.
Genuinely new: this is the initial publication of these trial results in the NEJM, with no indication that the underlying data are older material resurfacing.